Date: 2016-07-19
Type of information: Nomination
Compound:
Company: 4SC (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 19, 2016, 4SC AG announced the formation of an international Scientific Expert Panel. The goal of the expert panel is to further strengthen 4SC's leadership position in the development of epigenetic cancer drugs. Members of the panel, who are internationally recognized experts in the field of epigenetics and oncology, will provide 4SC with consultancy on research and clinical product development. The inaugural members of the iSEP are: Prof. Dr. Thomas Jenuwein, Director and Senior Group Leader at the Max Planck Institute of Immunobiology and Epigenetics (Freiburg, Germany); Coordinator of the European network of excellence "The Epigenome" and co-author of the benchmark textbook on epigenetics; research focus on epigenetic gene regulation
Dr. Charles B. Epstein, Senior Group Leader at the Broad Institute of MIT and Harvard (Cambridge (MA), USA); research focus on epigenome characterization to better understand cellular diversity in health and disease
Prof. Dr. Wolff Schmiegel, Head of the Department of Medicine, Knappschaftskrankenhaus Bochum GmbH, Ruhr-Universität Bochum (Germany) and Head of the Department of Gastroenterology / Hepatology, Berufsgenossenschaftliches Klinikum Bergmannsheil, Ruhr-Universität Bochum (Germany); medical specialist for internal medicine, gastroenterology, endocrinology, hematology and medical oncology
Financial terms:
Latest news:
